Cubist Pharmaceuticals, Inc. (CBST) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
JMP Securities Downgrades Cubist Pharmaceuticals (CBST) to Market Perform
July 23, 2014 6:40 AM EDTJMP Securities downgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Market Outperform to Market Perform and removed its price target (prior $80.00).
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $65.70 yesterday.
... More